Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for human UGT1A9 (compound)
Most Correlated Studies
- L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (2 of 2)
- L1000 CMAP Prostate cancer VCaP cells with gene overexpression perturbations
- L1000 CMAP Breast cancer MCF7 cells with gene overexpression perturbations
- L1000 CMAP Colorectal cancer HT 29 cells with gene overexpression perturbations
- Hepatocellular carcinoma HepaRG cells treated with mix of palmitate and oleate fatty acids
Most Relevant Literature
- UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro.
- The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste.
- Mechanism of dasabuvir inhibition of acetaminophen glucuronidation.
- The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by …
- Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Hu…
Most Relevant Clinical Trials
- Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colore…
- Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian…
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patie…
- Safety of Co-Administered CHI-554 and Alcohol
- A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Pat…
